Is it Ok to pause Mounjaro for one week - what are the consequences

The short version: a one-week pause is medically reasonable and unlikely to cause lasting harm, but the evidence here does not directly test your situation.

The retrieved studies show tirzepatide's main effects are on blood sugar and weight, with gastrointestinal side effects most common, often starting within days of the first dose [1][3]. One case series found that even seven days after the last dose, patients on GLP-1 drugs still had food in their stomachs before surgery [2]. That matters for you: the drug's effects on digestion linger well past a week, so pausing for one week does not fully clear the system.

What the evidence does not cover is your exact question. No retrieved study compares continuing versus pausing tirzepatide during or after an acute respiratory illness. No study here tracks recovery of heart rate variability or autonomic function after a missed dose. The persistence data shows many people stop these drugs entirely, with about half discontinuing within a year, and most who restart do so within two years [1]. That suggests a one-week gap is well within normal variation and restarting is generally feasible.

The real risks of a one-week pause are modest: blood sugar may rise if you have diabetes, and you may notice some return of appetite or gastrointestinal symptoms when you restart. The drug's half-life means a single missed dose does not cause a sudden withdrawal. For an acute illness, the bigger concern is dehydration and slowed stomach emptying, which the drug worsens [2][3]. Pausing during illness is the cautious choice, consistent with how similar metabolic drugs are handled.

My call: pausing for one week during an acute illness is reasonable and low-risk, but restart at the same dose only after you are fully recovered and eating normally. Confidence: low, because the retrieved evidence does not directly test your situation.